Jun 2012

Home >> Clinical Trials News Archive >> 2012 >> Jun 2012
CMO revenue could double in Europe, says Frost & Sullivan. New analysis from Frost & Sullivan, "European Pharmaceutical and Biotech Contract Manufacturing Markets," finds that the European pharmaceutical contract manufacturing market earned revenues of $10.02 billion in 2011 and estimates this to reach $20.75 billion in 2018. Over the same period, the European biotech contract manufacturing market is set to expand from $1.21 billion to an estimated $2.67 billion.

Medical Discoveries are Contracted Out as Research Organizations Move Abroad. According to a new study  released by GlobalData, contract research organisations (CROs) are becoming increasingly popular with medical device companies keen to improve their financial and operational efficiency, as increasingly complex clinical trials are needed to meet the approval of regulatory bodies.

On June 12, 2012, the Food and Drug Administration (FDA) announced in the Federal Register the availability of a draft guidance document entitled, “Considerations When Transferring Clinical Investigation Oversight to Another IRB.” This guidance discusses the regulatory responsibilities of institutional review boards (IRBs), clinical investigators, and sponsors when oversight of a previously approved clinical investigation under FDA’s jurisdiction is transferred from one IRB to another IRB.

Burrill & Co to raise $200m Israel life sciences fund. Sources inform ''Globes'' that Burrill & Company, one of the world's leading life sciences investment company is establishing a fund to invest in Israeli companies. The fund's special advisor Jeff Miller said, "We met with the Chief Scientist and we will see what collaboration is possible."

Biomed 2012 Conference Highlights Israel's Excellence. Tel Aviv hosts ILSI-Biomed 2012, the leading international conference in the biomedical, health care and life sciences industries.